8-K: AngioDynamics Reports Q1 FY27 Growth, CEO Transition

AngioDynamics announced its fiscal first quarter 2027 financial results, showcasing 6.9% total net sales growth driven by a 13.2% increase in the Med Tech segment, alongside the appointment of a new CEO.

Summary

• AngioDynamics reported first quarter fiscal year 2027 net sales of $80.9 million, a 6.9% increase year-over-year.
• The Med Tech segment was a key driver, with net sales of $39.9 million, up 13.2% year-over-year, marking its eighth consecutive quarter of double-digit growth.
• Med Device net sales were $41.0 million, a modest 1.4% increase.
• GAAP gross margin was 59.4%, an improvement of 410 basis points year-over-year, partly due to favorable pricing and the shift to Med Tech, though partially offset by manufacturing transition and inflation.
• The company reported a GAAP net loss of $7.1 million ($0.17 per share), an improvement from a $10.9 million loss ($0.26 per share) in the prior year.
• Adjusted EBITDA was $5.0 million, up from $2.2 million in the prior year.
• Eric Honroth was appointed President and CEO, effective November 2, 2026, succeeding Jim Clemmer who will retire.
• FDA IDE approval was received for the RELIEF study evaluating NanoKnife IRE for benign prostatic hyperplasia.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong execution in the Med Tech segment and reiterated guidance, though GAAP net loss persists.

Positives

• Continued double-digit growth in the Med Tech segment for the eighth consecutive quarter.
• Med Tech net sales increased by 13.2% to $39.9 million.
• Auryon peripheral atherectomy platform sales grew 14.7%.
• Mechanical Thrombectomy sales increased by 6.7% to $12.0 million, with AlphaVac sales up 37.4%.
• NanoKnife sales grew 29.0% to $8.3 million, driven by prostate procedures.
• GAAP gross margin improved to 59.4% from 55.3% in the prior year.
• Adjusted EBITDA increased to $5.0 million from $2.2 million.
• The company reiterated its fiscal year 2027 guidance, expecting net sales between $336.0M $341.0M and Adjusted EBITDA of $13.0M $16.0M.

Negatives

• The company reported a GAAP net loss of $7.1 million ($0.17 per share) for the quarter.
• Med Device net sales showed only a 1.4% increase.
• AngioVac sales declined by 5.9% compared to the prior year, though it grew sequentially.
• Cash used in operating activities was $15.3 million for the quarter.

Risks

• The scale and scope of the COVID-19 global pandemic.
• Ability to develop existing and new products.
• Technological advances and patents attained by competitors.
• Infringement of AngioDynamics technology or assertions that it infringes third-party technology.
• Competition from companies with substantially greater resources.
• Future actions by the FDA or other regulatory agencies.
• Overall economic conditions, including inflation, tariffs, labor shortages, and supply chain challenges.
• Results of pending or future clinical trials.

Future Outlook

The company is reiterating its fiscal year 2027 guidance, projecting net sales between $336.0 million and $341.0 million, Med Tech net sales growth of 12%-15%, flat Med Device net sales growth, a gross margin of 54%-55%, Adjusted EBITDA between $13.0 million and $16.0 million, and Adjusted EPS between ($0.29) and ($0.24).

Management Comments

• "Our first quarter results reflect the continued, consistent execution we've built into this business. Med Tech again led our growth, highlighted by Auryons 21st consecutive quarter of double-digit atherectomy growth, continued performance in Mechanical Thrombectomy, and ongoing strength in our NanoKnife oncology platform. We remain focused on the fundamentals that have driven our performance over the past several years, and were confident in our ability to deliver on the outlook we've laid out for fiscal 2027."
• "As I shared previously, after ten years leading this company, I have decided to retire, and the Board has completed a comprehensive search for my successor. Im pleased to share that Eric Honroth will become our next President and Chief Executive Officer. He brings the right experience and leadership to build on the foundation we've established, and I will remain closely involved to ensure a smooth transition."

Industry Context

StockSavvy.ai notes that AngioDynamics' performance aligns with a trend of growth in specialized medical technology segments, particularly those addressing vascular conditions and cancer treatment. The strong performance of the Med Tech segment, especially Auryon and NanoKnife, indicates successful market penetration and product adoption in areas with significant unmet needs. The company's focus on profitability and maintaining a debt-free balance sheet are positive indicators in a competitive MedTech landscape.

Comparison to Industry Standards

• The Med Tech segment's 13.2% year-over-year growth is robust and exceeds the typical growth rates seen in more mature medical device segments.
• Auryon's 21st consecutive quarter of double-digit growth suggests strong competitive positioning and market acceptance, outperforming many established players in the peripheral atherectomy market.
• NanoKnife's 29.0% growth, particularly in prostate procedures, indicates a successful expansion into new therapeutic areas, a strategy many medical device companies are pursuing.
• The overall net sales growth of 6.9% is solid, though the slower growth in the Med Device segment (1.4%) is a point of attention compared to the dynamic Med Tech segment.

Management Changes

Legal Proceedings

• Legal expenses related to litigation outside the normal course of business were $406,000 in Q1 FY27.

Stakeholder Impact

• Shareholders: Positive impact from continued revenue growth, improved profitability metrics (Adjusted EBITDA), and reiterated guidance, offset by ongoing GAAP net loss. CEO transition may introduce short-term uncertainty but the selection of an experienced leader is positive.
• Employees: Potential for continued growth and stability under new leadership, with a focus on execution.
• Customers: Continued access to innovative Med Tech products like Auryon and NanoKnife, with potential for new applications (BPH).
• Suppliers: Continued demand for components and materials supporting Med Tech and Med Device segments.

Next Steps

• Complete the transition to new President and CEO, Eric Honroth, effective November 2, 2026.
• Continue execution of fiscal year 2027 guidance.
• Enroll subjects in the RELIEF study evaluating NanoKnife IRE for benign prostatic hyperplasia.
• Monitor and manage tariff impacts and global economic conditions.

Key Dates

Recommendation

The company demonstrates strong execution in its Med Tech segment and reiterates guidance, which is positive. However, the persistent GAAP net loss and the upcoming CEO transition warrant a cautious 'hold' rating until the new leadership's strategy and performance are further established.

Keywords

Medical Technology, Med Tech, Med Device, Auryon, NanoKnife, Mechanical Thrombectomy, AngioVac, AlphaVac